Literature DB >> 22895942

Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults.

Lise Lotte Gluud1, Aleksander Krag.   

Abstract

BACKGROUND: Non-selective beta-blockers are used as a first-line treatment for primary prevention in patients with medium- to high-risk oesophageal varices. The effect of non-selective beta-blockers on mortality is debated and many patients experience adverse events. Trials on banding ligation versus non-selective beta-blockers for patients with oesophageal varices and no history of bleeding have reached equivocal results.
OBJECTIVES: To compare the benefits and harms of banding ligation versus non-selective beta-blockers as primary prevention in adult patients with endoscopically verified oesophageal varices that have never bled, irrespective of the underlying liver disease (cirrhosis or other cause). SEARCH
METHODS: In Febuary 2012, electronic searches (the Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Library, MEDLINE, EMBASE, and Science Citation Index Expanded) and manual searches (including scanning of reference lists in relevant articles and conference proceedings) were performed. SELECTION CRITERIA: Randomised trials were included irrespective of publication status, blinding, and language. DATA COLLECTION AND ANALYSIS: Review authors independently extracted data. All-cause mortality was the primary outcome. Intention-to-treat random-effects and fixed-effect model meta-analyses were performed. Results were presented as risk ratios (RR) and 95% confidence intervals (CI) with I(2) statistic values as a measure of intertrial heterogeneity. Subgroup, sensitivity, regression, and trial sequential analyses were performed to evaluate the robustness of the overall results, risks of bias, sources of intertrial heterogeneity, and risks of random errors. MAIN
RESULTS: Nineteen randomised trials on banding ligation versus non-selective beta-blockers for primary prevention in oesophageal varices were included. Most trials specified that only patients with large or high-risk oesophageal varices were included. Bias control was unclear in most trials. In total, 176 of 731 (24%) of the patients randomised to banding ligation and 177 of 773 (23%) of patients randomised to non-selective beta-blockers died. The difference was not statistically significant in a random-effects meta-analysis (RR 1.09; 95% CI 0.92 to 1.30; I(2) = 0%). There was no evidence of bias or small study effects in regression analysis (Egger's test P = 0.997). Trial sequential analysis showed that the heterogeneity-adjusted low-bias trial relative risk estimate required an information size of 3211 patients, that none of the interventions showed superiority, and that the limits of futility have not been reached. When all trials were included, banding ligation reduced upper gastrointestinal bleeding and variceal bleeding compared with non-selective beta-blockers (RR 0.69; 95% CI 0.52 to 0.91; I(2) = 19% and RR 0.67; 95% CI 0.46 to 0.98; I(2) = 31% respectively). The beneficial effect of banding ligation on bleeding was not confirmed in subgroup analyses of trials with adequate randomisation or full paper articles. Bleeding-related mortality was not different in the two intervention arms (29/567 (5.1%) versus 37/585 (6.3%); RR 0.85; 95% CI 0.53 to 1.39; I(2) = 0%). Both interventions were associated with adverse events. AUTHORS'
CONCLUSIONS: This review found a beneficial effect of banding ligation on primary prevention of upper gastrointestinal bleeding in patient with oesophageal varices. The effect on bleeding did not reduce mortality. Additional evidence is needed to determine whether our results reflect that non-selective beta-blockers have other beneficial effects than on bleeding.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895942     DOI: 10.1002/14651858.CD004544.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  51 in total

1.  Band ligation versus no intervention for primary prevention of upper gastrointestinal bleeding in adults with cirrhosis and oesophageal varices.

Authors:  Sonam Vadera; Charles Wei Kit Yong; Lise Lotte Gluud; Marsha Y Morgan
Journal:  Cochrane Database Syst Rev       Date:  2019-06-20

Review 2.  The Role of Therapeutic Endoscopy in Patients With Cirrhosis-Related Causes of Gastrointestinal Bleeding.

Authors:  Camille A Kezer; Neil Gupta
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

3.  Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding.

Authors:  Ayman Yosry Abd ElRahim; Rabab Fouad; Marwa Khairy; Aisha Elsharkawy; Waleed Fathalah; Haytham Khatamish; Omayma Khorshid; Mona Moussa; Moataz Seyam
Journal:  Hepatol Int       Date:  2017-11-28       Impact factor: 6.047

Review 4.  Platelet count, spleen length, and platelet count-to-spleen length ratio for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis.

Authors:  Agostino Colli; Juan Cristóbal Gana; Jason Yap; Thomasin Adams-Webber; Natalie Rashkovan; Simon C Ling; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2017-04-26

Review 5.  Emergent Transjugular Intrahepatic Portosystemic Shunt Creation in Acute Variceal Bleeding.

Authors:  Mithil B Pandhi; Andrew J Kuei; Andrew J Lipnik; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2020-03-04       Impact factor: 1.513

6.  Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib.

Authors:  Massimo Iavarone; Massimo Primignani; Sara Vavassori; Angelo Sangiovanni; Vincenzo La Mura; Raffaella Romeo; Massimo Colombo
Journal:  United European Gastroenterol J       Date:  2015-10-30       Impact factor: 4.623

7.  Primary prophylaxis of variceal bleeding.

Authors:  Marcus Robertson; Peter Hayes
Journal:  Hepatol Int       Date:  2018-02-02       Impact factor: 6.047

Review 8.  Pharmacologic prevention of variceal bleeding and rebleeding.

Authors:  Anna Baiges; Virginia Hernández-Gea; Jaime Bosch
Journal:  Hepatol Int       Date:  2017-12-05       Impact factor: 6.047

Review 9.  Interventions for preventing and managing advanced liver disease in cystic fibrosis.

Authors:  Senthil K Palaniappan; Nan Nitra Than; Aung Win Thein; Soe Moe; Indra van Mourik
Journal:  Cochrane Database Syst Rev       Date:  2017-08-29

Review 10.  Comorbidity in cirrhosis.

Authors:  Peter Jepsen
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.